Patent ID: 9624547
Date: 2017-04-18
CPC Classifications: C12Q,G01N

Claim:
1. A method for diagnosing the presence of breast cancer in a subject at risk for developing breast cancer, the method comprising: a) analyzing a saliva sample from the subject at risk for developing breast cancer with an assay that specifically detects at least nine biomarkers in the saliva sample, wherein the nine biomarkers are S100A8 (S 100 calcium binding protein A8)(SEQ ID NO: 1), CSTA (cystatin A)(SEQ ID NO:2), GRM1 (glutamate receptor, metabotropic 1)(SEQ ID NO: 3), TPT1 (tumor protein, translationally-controlled 1)(SEQ ID NO:4), GRIK1 (glutamate receptor, ionotropic, kainate 1)(SEQ ID NO: 5), H6PD (hexose-6-phosphate dehydrogenase)(SEQ ID NO: 6), IGF2BP1 (insulin-like growth factor 2 mRNA binding protein 1)(SEQ ID NO: 7), MDM4 (3T3 cell double minute 4)(SEQ ID NO: 8), and CA6 (carbonic anhydrase VI)(SEQ ID NO: 9); b) detecting that the at least nine biomarkers are differentially expressed in the sample relative to a control sample from a subject without breast cancer, thereby detecting the presence of breast cancer in the subject; and c) administering a breast cancer treatment regimen to the subject, wherein the treatment regimen is selected from the group consisting of chemotherapy, hormonal therapy, radiotherapy, immunotherapy, and surgical removal of breast tissue.